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LETTERS TO THE EDITORRegarding “Derivation and validation of a practical risk
score for prediction of mortality after open repair of
ruptured abdominal aortic aneurysms in a U.S.
regional cohort and comparison to existing scoring
systems”
We read with interest the article by Robinson et al.1 Several
series have now questioned the validity of the Glasgow Aneurysm
Score, Hardman Index, and Vancouver score in the prediction of
outcome after ruptured abdominal aortic aneurysm (RAAA).2,3
The authors have now also demonstrated a lack of external validity
for the Edinburgh Ruptured Aneurysm Score. These four risk-
scoring instruments were all derived from clinically diverse Scot-
tish, Australian, and Canadian specialist and nonspecialist vascular
practices in an era of exclusively open surgical repair for RAAAs.
Poor performance in a contemporary series of selected American
patients undergoing open repair of RAAAs, that also offers emer-
gency endovascular aneurysm repair is unsurprising.
Twenty years of clinical research has failed to clarify whether
outcome in patients with RAAAs can be predicted accurately. The
existing literature suggests there are patient-related preoperative
variables associated with perioperative death after AAA rupture.
However, it must be noted that population-related, institutional-
related, health systems-related, and surgeon-related variables have
a profound effect on outcome, too.4,5 When faced with such vari-
ability, the goal of a precise, reliable instrument with generalizable
validity seems unattainable.
There are certain universal deﬁciencies common to the
application of all scoring systems. Selection bias in the recruit-
ment of patients to the original data set upon which a scoring
instrument is derived can impair performance. The performance
of a scoring system is said to work best when it is customized to
the behavior of a local environment and population. As a result,
our own risk modeling was unique and highly speciﬁc toward our
data. When applied to data from other centers, it will fail to
demonstrate the same good ﬁt. Furthermore, with the introduc-
tion of endovascular repair of RAAAs, and the potential improve-
ments in patient survival, risk-scoring data sets require further
analysis, remodelling, or recalibration to ensure predictive power
is maintained.
The quality and utility of the Vascular Study Group of New
England (VSGNE) data is irrefutable. Although the number of
patients turned down for surgical intervention and the proportion
treatedwith endovascular aneurysmrepairwouldenhance interpreta-
tion of the data, this series is a step in the right direction to develop
accurate modern risk stratiﬁcation tools for patients with RAAAs.
The VSGNE has the opportunity to ﬁrst apply the risk tool from
this development data set on a separate VSGNE data set to conﬁrm
internal validity and permit ﬁne-tuning before application to external
data sets.
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We thank Tambyraja and colleagues for their thoughtful
response to our recent manuscript. Tambyraja and colleagues in
Edinburg have extensive experience in this area of study, and
they rightly point out that, even after 20 years of research, the
prediction of outcome after repair of a ruptured abdominal aortic
aneurysm (RAAA) has remained elusive.
These authors emphasize that the performance of any scoring
system will always be best when applied to the local environment
from which it is derived. We agree with this assessment, because
there are many local factors related to the patient as well as to
the institutions and surgeons that will affect outcome. Surgeons
and institutions must therefore be ever mindful of the factors
that impact outcome in their own environment so that clinical
care and decision making can be optimized. Nevertheless, a scoring
system with generalizable validity is a worthwhile goal because it
allows for the risk adjustment that is necessary for fair and valid
comparative audit. Given the strength of the Vascular Study Group
of New England data set, we believe that this analysis represents
progress toward that goal. We agree that validation of our scoring
system in larger data sets, both internal and external, is necessary to
show broad generalizability. We plan this in future work.
Tambyraja and colleagues also point out that the availability of
endovascular aneurysm repair may affect the predictive ability of
the scoring system in certain cohorts of patients. This is an excel-
lent point that echoes the discussion in our article. We plan to vali-
date this scoring system in patients undergoing endovascular repair
of RAAA. We believe that a scoring system that accurately predicts
outcome in patients undergoing open and endovascular repair of
RAAA will have broad applicability and will allow for more accu-
rate comparison of the outcomes of open and endovascular repair.
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Regarding “Intraoperative use of dextran is associated
with cardiac complications after carotid
endarterectomy”
We read with great interest the recent article by Farber et al1
on behalf of the Vascular Study Group of New England regarding
the high cardiovascular complication rate associated with the use
of dextran as an antithrombotic agent after carotid endarterec-
tomy (CEA). The strongest evidence to support intravenous
dextran after CEA is based on its selective use when patients
have persistently high transcranial Doppler (TCD)-detected
microembolization.2Fig. Microemboli signals (MES) after carotid endarterectomy in
patients on single-antiplatelet therapy before surgery.C, Dextran-
40 (n ¼ 28); B, patients (n ¼ 4) who developed early stroke,
despite dextran-40 infusion; -, tiroﬁban (n ¼ 32); :, no addi-
tional antiplatelet treatment (n ¼ 36).6 Reproduced with permis-
sion from Saedon et al.6Cerebral microemboli appear to be primarily solid platelet
aggregates. Microemboli are associated with a high risk of subse-
quent stroke and can be successfully controlled with a number of
antiplatelet agents, including aspirin, dextran, and S-nitrosogluta-
thione.3 We found that it was possible to control microemboli in
patients with recurrent or crescendo transient ischemic attacks
using preoperative TCD-directed dextran therapy, and so safely
defer CEA until the next elective list.4 However in this small
cohort, the cardiovascular side effects of dextran appeared exces-
sive. We therefore attempted to use a more selective TCD-
directed intravenous antiplatelet agent, a glycoprotein IIb/IIIa
receptor antagonist (tiroﬁban), to control transient cerebral
microemboli both before and after CEA.5 In view of our
previous experience of the effectiveness and tolerability of the
intravenous glycoprotein IIb/IIIa antagonist antiplatelet agent
(tiroﬁban),5 we have recently compared the efﬁcacy of dextran
with tiroﬁban and found that TCD-directed tiroﬁban therapy
appears more effective than dextran-40 in suppression of cerebral
microemboli after CEA, with a lower side effect proﬁle6 (Fig).
Our ﬁndings support the authors’ conclusions that dextran
has a limited role in carotid endarterectomy. In our opinion,
TCD-directed tiroﬁban would be a safer and more efﬁcacious
approach to reduce stroke risk after carotid endarterectomy in
these patients.Christopher Imray, PhD, FRCS, FRCP, FRGS
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Multiple studies have demonstrated the efﬁcacy of transcranial
Doppler (TCD)-directed dextran therapy during carotid endarter-
ectomy (CEA).1-3 In our recent review of 6641 CEAs performed
within the auspices of the Vascular Study Group of New England,4
we found perioperative infusion of dextran was not correlated with
lower stroke rates but rather was associated with increased postop-
erative cardiac complications, including myocardial infarction and
congestive heart failure. We concluded that there was limited clin-
ical utility for the routine use of dextran during CEA.
We read with great interest the article by Saedon et al5
regarding the efﬁcacy of TCD- directed antiplatelet therapy during
CEA. These authors found TCD-directed infusion of the glyco-
protein IIb/IIIa antagonist tiroﬁban was more effective than
dextran in reducing transient cerebral microemboli before and
after CEA.5 Their conclusions suggest a potential role of TCD-
directed tiroﬁban infusion during CEA. Although these ﬁndings
are provocative, widespread use of tiroﬁban cannot be recommen-
ded from on these data alone. Further investigation of this agent in
CEA patients is warranted.
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